195 related articles for article (PubMed ID: 16493041)
1. Identification of oncofetal antigen/immature laminin receptor protein epitopes that activate BALB/c mouse OFA/iLRP-specific effector and regulatory T cell clones.
Rohrer JW; Barsoum AL; Coggin JH
J Immunol; 2006 Mar; 176(5):2844-56. PubMed ID: 16493041
[TBL] [Abstract][Full Text] [Related]
2. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.
Siegel S; Wagner A; Kabelitz D; Marget M; Coggin J; Barsoum A; Rohrer J; Schmitz N; Zeis M
Blood; 2003 Dec; 102(13):4416-23. PubMed ID: 12869512
[TBL] [Abstract][Full Text] [Related]
3. 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers.
Coggin JH; Barsoum AL; Rohrer JW
Anticancer Res; 1999; 19(6C):5535-42. PubMed ID: 10697612
[TBL] [Abstract][Full Text] [Related]
4. Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes.
Rohrer JW; Barsoum AL; Dyess DL; Tucker JA; Coggin JH
J Immunol; 1999 Jun; 162(11):6880-92. PubMed ID: 10352310
[TBL] [Abstract][Full Text] [Related]
5. Differential recognition of murine tumor-associated oncofetal transplantation antigen and individually specific tumor transplantation antigens by syngeneic cloned BALB/c and RFM mouse T cells.
Rohrer JW; Rohrer SD; Barsoum A; Coggin JH
J Immunol; 1994 Jan; 152(2):754-64. PubMed ID: 7904290
[TBL] [Abstract][Full Text] [Related]
6. Production, safety and antitumor efficacy of recombinant Oncofetal Antigen/immature laminin receptor protein.
Barsoum AL; Liu B; Rohrer JW; Coggin JH; Tucker JA; Pannell LK; Schwarzenberger PO
Biomaterials; 2009 Jun; 30(17):3091-9. PubMed ID: 19268360
[TBL] [Abstract][Full Text] [Related]
7. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10.
Rohrer JW; Coggin JH
J Immunol; 1995 Dec; 155(12):5719-27. PubMed ID: 7499859
[TBL] [Abstract][Full Text] [Related]
8. Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function.
Dumortier H; van Mierlo GJ; Egan D; van Ewijk W; Toes RE; Offringa R; Melief CJ
J Immunol; 2005 Jul; 175(2):855-63. PubMed ID: 16002683
[TBL] [Abstract][Full Text] [Related]
9. Anti-idiotypic antibodies against UV-induced tumor-specific CTL clones. Preparation in syngeneic combination.
Kuribayashi K; Tanaka C; Matsubayashi Y; Masuda T; Udono H; Abe M; Nakayama E; Shiku H
J Immunol; 1988 Dec; 141(11):4074-80. PubMed ID: 2460558
[TBL] [Abstract][Full Text] [Related]
10. Distinction of mouse CD8+ suppressor effector T cell clones from cytotoxic T cell clones by cytokine production and CD45 isoforms.
Inoue T; Asano Y; Matsuoka S; Furutani-Seiki M; Aizawa S; Nishimura H; Shirai T; Tada T
J Immunol; 1993 Mar; 150(6):2121-8. PubMed ID: 8450205
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
12. Characterization of RFM mouse T lymphocyte anti-oncofetal antigen immunity in apparent tumor-free, long-term survivors of sublethal X-irradiation by limiting dilution T lymphocyte cloning.
Rohrer JW; Culpepper C; Barsoum AL; Coggin JH
J Immunol; 1995 Mar; 154(5):2266-80. PubMed ID: 7868899
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity.
Dorothée G; Vergnon I; Menez J; Echchakir H; Grunenwald D; Kubin M; Chouaib S; Mami-Chouaib F
J Immunol; 2002 Jul; 169(2):809-17. PubMed ID: 12097384
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies specific for oncofetal antigen--immature laminin receptor protein: Effects on tumor growth and spread in two murine models.
McClintock SD; Warner RL; Ali S; Chekuri A; Dame MK; Attili D; Knibbs RK; Aslam MN; Sinkule J; Morgan AC; Barsoum A; Smith LB; Beer DG; Johnson KJ; Varani J
Cancer Biol Ther; 2015; 16(5):724-32. PubMed ID: 25799942
[TBL] [Abstract][Full Text] [Related]
15. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.
zum Büschenfelde CM; Metzger J; Hermann C; Nicklisch N; Peschel C; Bernhard H
J Immunol; 2001 Aug; 167(3):1712-9. PubMed ID: 11466395
[TBL] [Abstract][Full Text] [Related]
16. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the Fas ligand/Fas-dependent apoptosis of antiretroviral, class I MHC tetramer-defined, CD8+ CTL by in vivo retrovirus-infected cells.
Rich RF; Green WR
J Immunol; 2002 Mar; 168(6):2751-8. PubMed ID: 11884442
[TBL] [Abstract][Full Text] [Related]
18. Generation of IL-2-dependent cytolytic T lymphocytes (CTLs) with altered TCR responses derived from antigen-dependent CTL clones.
Gullo CA; Esser MT; Fuller CL; Lam Braciale V
J Immunol; 1999 Jun; 162(11):6466-72. PubMed ID: 10352261
[TBL] [Abstract][Full Text] [Related]
19. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.
Siegel S; Wagner A; Friedrichs B; Wendeler A; Wendel L; Kabelitz D; Steinmann J; Barsoum A; Coggin J; Rohrer J; Dreger P; Schmitz N; Zeis M
J Immunol; 2006 Jun; 176(11):6935-44. PubMed ID: 16709854
[TBL] [Abstract][Full Text] [Related]
20. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
